Sally Church on Pharma Strategy Blog discusses the issue of to what extent hormone replacement therapy (HRT) is linked to a higher incidence of breast cancer?
Recent data published in the Journal of the American Medical Association (JAMA) showed a reduction in breast cancer incidence for those taking conjugate equine estrogens. This is in sharp contrast to other studies that suggest a higher incidence of breast cancer in HRT users.
As Sally discusses in her thoughtful post, part of the reason for the difference “may lie in the type of hormone treatments given (estrogen only versus combination therapy) and variations in patient groups.”
Additionally, Sally notes that the differences “can be explained in the long-term follow-up after treatment.”
You can read more about this controversial topic on Pharma Strategy Blog.